EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation

Amber Tiemens, Christophe Sauboin, Sharon Wolters, Simon James Bond, Judith Olga Maria Bentvelzen, Susana Monteiro, Seán Walsh, Maarten Jacobus Postma

Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2026 · 26 (6) · 783-793

DOI: 10.1080/14737167.2026.2691190 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 22.06.2026. Verfasst von Amber Tiemens und 7 weiteren Autor:innen. Beteiligte Einrichtung: Market Access and HEOR, Asc Academics B.V., Groningen, The Netherlands. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalAntineoplastic AgentsHumansGuidelines as TopicSpainFranceCooperative BehaviorEuropean UnionInternational CooperationGermany

Stichwörter der Autor:innen

Evidence generationhealth technology assessmentjoint clinical assessmentmarket accessoncology drugs

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Market Access and HEOR, Asc Academics B.V., Groningen, The Netherlands.
  • Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Global HEOR, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Market Access, Boehringer Ingelheim Portugal, Lda, Lisbon, Portugal.
  • Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Tiemens, A., Sauboin, C., Wolters, S., Bond, S. J., Bentvelzen, J. O. M., Monteiro, S., Walsh, S., & Postma, M. J. (2026). Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation. Expert Review of Pharmacoeconomics & Outcomes Research, 26(6), 783-793. https://doi.org/10.1080/14737167.2026.2691190

Vancouver

Tiemens A, Sauboin C, Wolters S, Bond SJ, Bentvelzen JOM, Monteiro S, et al. Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation. Expert Review of Pharmacoeconomics & Outcomes Research. 2026;26(6):783-793. doi:10.1080/14737167.2026.2691190

BibTeX
@article{Tiemens2026,
  author = {Tiemens, Amber and Sauboin, Christophe and Wolters, Sharon and Bond, Simon James and Bentvelzen, Judith Olga Maria and Monteiro, Susana and Walsh, Seán and Postma, Maarten Jacobus},
  title = {Differences in evidentiary requirements for oncology drug assessments across health technology assessment bodies in Germany, Spain, and France, the European Medicines Agency, and the EU Health Technology assessment regulation},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {783--793},
  doi = {10.1080/14737167.2026.2691190}
}
Kostenlos starten →